                         SEQUENCE LISTING

<110>  CARMEL-HAIFA UNIVERSITY ECONOMIC CORP
 
<120>  SYNTHETIC ANTI-INFLAMMATORY PEPTIDES AND USE THEREOF

<130>  CRML/005 PCT

<150>  US 61/815,743
<151>  2013-04-25

<160>  21    

<170>  PatentIn version 3.5

<210>  1
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide

<400>  1

Phe Lys Glu 
1           


<210>  2
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide

<400>  2

Tyr Lys Glu 
1           


<210>  3
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide

<400>  3

Phe Lys Asp 
1           


<210>  4
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide

<400>  4

Phe Lys Glu Cys His 
1               5   


<210>  5
<211>  35
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide

<400>  5

Phe Lys Glu Ala Ala Ala Ala Ala Phe Lys Glu Ala Ala Ala Ala Ala 
1               5                   10                  15      


Phe Lys Glu Ala Ala Ala Ala Ala Phe Lys Glu Ala Ala Ala Ala Ala 
            20                  25                  30          


Phe Lys Glu 
        35  


<210>  6
<211>  35
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide

<400>  6

Phe Lys Glu Gly Gly Gly Gly Gly Phe Lys Glu Gly Gly Gly Gly Gly 
1               5                   10                  15      


Phe Lys Glu Gly Gly Gly Gly Gly Phe Lys Glu Gly Gly Gly Gly Gly 
            20                  25                  30          


Phe Lys Glu 
        35  


<210>  7
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal acetyl group

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  C-terminal amide group

<400>  7

Phe Lys Glu 
1           


<210>  8
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal acetyl group

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  C-terminal amide group

<400>  8

Ala Ala Ala Ala Ala Phe Lys Glu Ala Ala Ala Ala Ala Phe Lys Glu 
1               5                   10                  15      


Ala Ala Ala Ala Ala Phe Lys Glu Ala Ala Ala Ala Ala 
            20                  25                  


<210>  9
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  X1 is an amino acid, a peptide of 2 to 7 amino acids other than 
       YR and LDH, a chemical derivatizing group or is absent

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  X2 is an amino acid other than K and R, a spacer of 2 to 7 amino 
       acids comprising a plurality of A and/or G residues, or is absent

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  X3 is an amino acid other than V, K and R, a spacer of 2 to 7 
       amino acids comprising a plurality of A and/or G residues, or is 
       absent

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X4 is an amino acid, a peptide of 2 to 7 amino acids, a chemical 
       derivatizing group or is absent, when X3 is absent, X4 is not 
       HWR, LEG, LEGWEP, CTV, CTVEY, CTVEYEL, CHL, CHLA or HLA

<400>  9

Xaa Xaa Phe Lys Glu Xaa Xaa 
1               5           


<210>  10
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide of formula Ib


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  X1 is an amino acid, a peptide of 2 to 7 amino acids, a chemical 
       derivatizing group or is absent

<220>
<221>  misc_feature
<222>  (2)..(2)
<223>  X2 is an amino acid, a spacer of 2 to 7 amino acids comprising a 
       plurality of A and/or G residues, or is absent

<220>
<221>  misc_feature
<222>  (2)..(6)
<223>  the peptide is provided with the proviso that X3-F-K-E-X4 are 
       repeated 2-5 times

<220>
<221>  misc_feature
<222>  (2)..(6)
<223>  the peptide of Formula Ib is provided with the proviso that 
       X3-F-K-E-X4 is repeated 2-5 times

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  X3 is an amino acid, a spacer of 2 to 7 amino acids comprising a 
       plurality of A and/or G residues, or is absent

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  X4 is an amino acid, a peptide of 2 to 7 amino acids, a chemical 
       derivatizing group or is absent

<400>  10

Xaa Xaa Phe Lys Glu Xaa Xaa 
1               5           


<210>  11
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  X1 is an amino acid, a peptide of 2-7 amino acids other than RR, 
       MDIDP, and KKNWIQ, a chemical derivatizing group or is absent

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  X2 is an amino acid, a spacer of 2-7 amino acids comprising a 
       plurality of A and/or G residues, or is absent; wherein when X1 
       is absent and X2 is an amino acid, X2 is not Y or E

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  X3 is an amino acid, a spacer of 2-7 amino acids comprising a 
       plurality of A and/or G residues, or is absent; wherein X4 is 
       absent and X3 is an amino acid, X3 is not Y

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X4 is an amino acid, a peptide of 2 to 7 amino acids, a chemical 
       derivatizing group or is absent; wherein when X3 is absent, X4 is
       not KEK

<400>  11

Xaa Xaa Tyr Lys Glu Xaa Xaa 
1               5           


<210>  12
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide of formula IIb


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  X1 is an amino acid, a peptide of 2-7 amino acids, a chemical 
       derivatizing group or is absent

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  X2 is an amino acid, a spacer of 2-7 amino acids comprising a 
       plurality of A and/or G residues, or is absent

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  the peptide of formula IIb is provided with the proviso that the 
       sequence X2-Y-K-E-X3 is repeated 2-5 times

<220>
<221>  MISC_FEATURE
<222>  (2)..(6)
<223>  the peptide of formula IIb is provided with the proviso that 
       X2-Y-K-E-X3 is repeated 2-5 times

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  X3 is an amino acid, a spacer of 2-7 amino acids comprising a 
       plurality of A and/or G residues, or is absent

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X4 is an amino acid, a peptide of 2-7 amino acids, a chemical 
       derivatizing group or is absent

<400>  12

Xaa Xaa Tyr Lys Glu Xaa Xaa 
1               5           


<210>  13
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide

<400>  13

Leu Glu Gly Trp Glu Pro 
1               5       


<210>  14
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide

<400>  14

Cys Thr Val Glu Tyr 
1               5   


<210>  15
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide

<400>  15

Cys Thr Val Glu Tyr Glu Leu 
1               5           


<210>  16
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide

<400>  16

Cys His Leu Ala 
1               


<210>  17
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide

<400>  17

Ser Leu Asp His 
1               


<210>  18
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide

<400>  18

Met Asp Ile Asp Pro 
1               5   


<210>  19
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide

<400>  19

Lys Lys Asn Trp Ile Gln 
1               5       


<210>  20
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide

<400>  20

Glu Arg His Asn Lys 
1               5   


<210>  21
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide

<400>  21

Phe Lys Glu Cys His Leu Ala 
1               5           


